Kansas City - New Vaccine Surveillance Network (KC-NVSN)

项目总结： 堪萨斯城-新疫苗监测网络(KC-NVSN)计划于2009年建立，旨在开展 儿童急性胃肠炎(AGE)疾病的以人群为基础的、实验室确认的积极监测 在密苏里州堪萨斯城(KC)的儿童慈悲医院寻求治疗。该计划随后得到了扩展 2015年，将住院ARI儿童纳入住院(IP)环境。 在目前的提案中，KC-NVSN计划寻求继续现有的儿科年龄IP和门诊 (Op)在6个县的KC大都市区进行监测，在密苏里州杰克逊县进行ARI IP监测。在……里面 此外，我们将把ARI监视从杰克逊县扩展到OP，访问主要的CMH紧急情况 部门。年龄和时间匹配的健康对照儿童也将被纳入。符合条件的儿童参观或 根据以上定义进入我们的医院系统，将使用批准的许可和同意表格进行登记 由CMH的机构审查委员会(IRB)提供。我们将进行家长面谈，收集病历数据 并从注册儿童中检索流感和轮状病毒疫苗信息的硬拷贝。临床 从儿童身上收集的样本将被检测轮状病毒(和其他胃肠道病原体，例如诺沃克病毒 拟议的次级项目)和来自呼吸道样本的22种呼吸道病原体，包括 流感亚型和其他非流感病毒，如RSV、EV-D68等。 KC-NVSN计划将提供基于人口的估计，以实现以下具体目标： 1.评估疫苗预防轮状病毒和流感的有效性 疾病按试验阴性病例对照研究设计，采用实验室确认试验 被录取的儿童。 2.评估选定的年龄病原体和非流感病毒病原体的负担，包括 在校儿童呼吸道合胞病毒和EV-D68感染情况调查 KC-NVSN计划将提供与其他地理上不同的地点相结合的数据，以估计 社区获得性年龄和ARI的全国发病率、负担和病因学。轮状病毒的VE和 将计算季节性流感疫苗接种，以衡量接种疫苗的影响。这个网络还将 处理与儿科传染病自然史有关的几个重要科学问题， 传播动态、疫苗对目标人群和弱势人群的影响及其影响因素 疫苗的有效性。从这个网络产生的监控数据将提供及时和高度有用的 为旨在控制年龄和急性呼吸道感染的公共卫生措施和儿科疫苗相关政策提供信息的数据 在美国儿童中。

Project Summary: The Kansas City-New Vaccine Surveillance Network (KC-NVSN) program was established in 2009 to conduct population-based, laboratory-confirmed, active surveillance of acute gastroenteritis (AGE) illness in children seeking care at Children's Mercy Hospital, in Kansas City (KC), MO. The program was subsequently expanded in 2015 to include hospitalized ARI children in inpatient (IP) settings. In the current proposal, the KC-NVSN program seeks to continue the existing pediatric AGE IP and outpatient (OP) surveillance in the six county KC metropolitan area and ARI IP surveillance in Jackson County, MO. In addition, we will expand ARI surveillance to OP from Jackson County visiting the main CMH emergency department. Age and time matched healthy control children will also be enrolled. Eligible children visiting or admitted to our hospital system as defined above will be enrolled using permission and assent forms approved by the institutional review board (IRB) of CMH. We will conduct parent interviews, collect medical chart data and retrieve hard copies of vaccine information for influenza and rotavirus from enrolled children. Clinical specimens collected from children will be tested for rotavirus (and other GI pathogens, e.g. norovirus in proposed subprojects) in stool and 22 respiratory pathogens from respiratory specimen including specific influenza subtypes and other non-influenza viruses, such as RSV, EV-D68 etc. The data collected from the KC-NVSN program will provide population-based estimates to address the following specific aims: 1. To assess vaccine effectiveness (VE) in preventing medically attended rotavirus and influenza illness by the test-negative case-control study design using laboratory confirmed testing among enrolled children. 2. To assess the burden of select AGE pathogens and non-influenza viral pathogens, including respiratory syncytial virus and EV-D68 among enrolled children. The KC-NVSN program will provide data to be combined with other geographically diverse sites to estimate the national incidence, burden, and etiology of community-acquired AGE and ARI. The VE for rotavirus and seasonal influenza vaccinations will be calculated to measure the impact of vaccination. This network will also address several important scientific questions related to natural history of pediatric infectious diseases, transmission dynamics, impact of vaccine on targeted and vulnerable population and factors that influence vaccine effectiveness. The surveillance data generated from this network will provide timely and highly useful data to inform public health measures and pediatric vaccine-related policies aimed at controlling AGE and ARI in US children.